An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with ICI by activating cytotoxic T- and NK-cell-mediated anti-...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W. Salcedo, Dennis Verzijl, David Eisel, Christian Grunwitz, Lena M Kranz, Mathias Vormehr, David P.E. Satijn, Mustafa Diken, Sebastian Kreiter, Kate Sasser, Tahamtan Ahmadi, Özlem Türeci, Esther C.W. Breij, Maria Jure-Kunkel, Ugur Sahin
Format:	Artigo
Język:	Inglês
Wydane:	Taylor & Francis Group 2022-12-01
Seria:	OncoImmunology
Hasła przedmiotowe:	pd-l1 4-1bb bispecific antibody checkpoint immunotherapy t cells
Dostęp online:	http://dx.doi.org/10.1080/2162402X.2022.2030135
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!